The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 344:137-138 January 11, 2001 Number 2
NextNext

Treatment of Renal-Cell Cancer by Transplantation of Allogeneic Stem Cells

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Childs et al. (Sept. 14 issue)1 report the spectacular success of nonmyeloablative allogeneic stem-cell transplantation in a subgroup of patients with metastatic renal-cell carcinoma. Only the patients with clear-cell carcinomas had responses. Previous work indicates that most renal-cell carcinomas with clear-cell histology are caused by mutation of the von Hippel–Lindau tumor-suppressor gene, located on chromosome band 3p26.2,3 The von Hippel–Lindau gene produces two proteins that can suppress tumor formation in clear-cell renal-cell carcinoma in a nude-mouse model.4 My colleagues and I have demonstrated that the von Hippel–Lindau gene, in addition to its tumor-suppressor function, protects cells from . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.